NMDA receptor-mediated modulation on glutamine synthetase and glial glutamate transporter GLT-1 is involved in the antidepressant-like and neuroprotective effects of guanosine

Chem Biol Interact. 2023 Apr 25:375:110440. doi: 10.1016/j.cbi.2023.110440. Epub 2023 Mar 4.

Abstract

Guanosine has been reported to elicit antidepressant-like responses in rodents, but if these actions are associated with its ability to afford neuroprotection against glutamate-induced toxicity still needs to be fully understood. Therefore, this study investigated the antidepressant-like and neuroprotective effects elicited by guanosine in mice and evaluated the possible involvement of NMDA receptors, glutamine synthetase, and GLT-1 in these responses. We found that guanosine (0.05 mg/kg, but not 0.01 mg/kg, p. o.) was effective in producing an antidepressant-like effect and protecting hippocampal and prefrontocortical slices against glutamate-induced damage. Our results also unveiled that ketamine (1 mg/kg, but not 0.1 mg/kg, i. p, an NMDA receptor antagonist) effectively elicited antidepressant-like actions and protected hippocampal and prefrontocortical slices against glutamatergic toxicity. Furthermore, the combined administration of sub-effective doses of guanosine (0.01 mg/kg, p. o.) with ketamine (0.1 mg/kg, i. p.) promoted an antidepressant-like effect and augmented glutamine synthetase activity and GLT-1 immunocontent in the hippocampus, but not in the prefrontal cortex. Our results also showed that the combination of sub-effective doses of ketamine and guanosine, at the same protocol schedule that exhibited an antidepressant-like effect, effectively abolished glutamate-induced damage in hippocampal and prefrontocortical slices. Our in vitro results reinforce that guanosine, ketamine, or sub-effective concentrations of guanosine plus ketamine protect against glutamate exposure by modulating glutamine synthetase activity and GLT-1 levels. Finally, molecular docking analysis suggests that guanosine might interact with NMDA receptors at the ketamine or glycine/d-serine co-agonist binding sites. These findings provide support for the premise that guanosine has antidepressant-like effects and should be further investigated for depression management.

Keywords: Antidepressant; Glutamate; Guanosine; Hippocampus; Ketamine.

MeSH terms

  • Amino Acid Transport System X-AG / metabolism
  • Amino Acid Transport System X-AG / pharmacology
  • Animals
  • Antidepressive Agents / pharmacology
  • Depression / metabolism
  • Excitatory Amino Acid Transporter 2
  • Glutamate-Ammonia Ligase / metabolism
  • Glutamate-Ammonia Ligase / pharmacology
  • Glutamic Acid / pharmacology
  • Guanosine / metabolism
  • Guanosine / pharmacology
  • Hippocampus
  • Ketamine* / pharmacology
  • Mice
  • Molecular Docking Simulation
  • Neuroprotective Agents* / metabolism
  • Neuroprotective Agents* / pharmacology
  • Receptors, N-Methyl-D-Aspartate / metabolism

Substances

  • Amino Acid Transport System X-AG
  • Antidepressive Agents
  • Glutamate-Ammonia Ligase
  • Glutamic Acid
  • Guanosine
  • Ketamine
  • Neuroprotective Agents
  • Receptors, N-Methyl-D-Aspartate
  • Excitatory Amino Acid Transporter 2